Horizon Discovery Appoints Eric Rhodes as Chief Technical Officer
In both roles he was responsible for the commercialization of gene-editing technology for which he closed multimillion dollar strategic licensing deals with over 25 of the top pharma and biotech companies in the world. He also was a part of the senior management team that successfully took Sangamo BioSciences public in 2000.
At Horizon, Eric will be the Company’s primary expert in human and mammalian gene targeting methods, with significant input into R&D and marketing for rAAV-mediated genome editing technology. He will also play a key role in supporting sites participating in Horizon’s Centers of Excellence Program.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.